ArticleMolecular psychiatry2025
Plasma neurofilament light reflects more severe manifestation of Alzheimer's disease in men.
Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hospital-treated infection associated with Alzheimer's disease pathology: underlying mechanisms.Molecular psychiatry · 2026Review
- Advancing Alzheimer's disease research in China: insights, innovations, and future directions from the chinese preclinical Alzheimer's disease study (CPAS).Molecular psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Plasma neurofilament light (NfL) protein is a promising non-invasive biomarker for detecting neuronal damage in Alzheimer's disease (AD). However, its clinical utility is limited by the lack of standardized threshold values. Sex is an important factor that should be considered when setting these thresholds, but only a few studies have examined sex differences in plasma NfL levels in AD, with inconsistent findings. Even fewer have explored whether sex influences the relationship between plasma NfL levels and disease severity. To investigate this, we first analyzed data from 860 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Linear regression models were used to assess sex differences in the correlation between plasma NfL levels, cognitive deficits, and neuroimaging metrics. A Cox model with bootstrap resampling was used to evaluate sex differences in dementia risk, calculating the hazard ratio for men versus women for a given increase in plasma NfL. Our results showed that, compared to women, men with higher plasma NfL levels exhibited more severe cognitive defects and brain hypometabolism, along with smaller hippocampal volume. These findings were validated using data from 619 participants in the Chinese Preclinical Alzheimer's Disease Study (C-PAS) cohort and 86 participants from a publicly available dataset. In addition, we found that increase in plasma NfL levels were predictive of faster cognitive decline and a higher likelihood of AD progression in men compared to women. In conclusion, sex differences influence the relationship between plasma NfL levels and AD symptoms. Men exhibit greater cognitive and neuropathological defects with rising plasma NfL levels, underscoring the need for considering sex when using NfL as a biomarker for neuronal damage in AD.
Indexed as
Identifiers
40796698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.